Related Experiment Video
Updated: Apr 10, 2026
08:45
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
14.3K
CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.
1Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia. ruzila@kk.usm.my
Pharmacology
|June 5, 2010
Summary
Genetic variations in CYP3A4 significantly impact how repaglinide is processed in the body, affecting its pharmacokinetic profile. This highlights the importance of CYP3A4 polymorphisms in understanding repaglinide metabolism variability.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Clinical Pharmacology
Background:
- Repaglinide is an oral hypoglycemic agent used to manage type 2 diabetes.
- Cytochrome P450 enzymes, particularly CYP3A4 and CYP2C8, are involved in drug metabolism.
- Interindividual variability in drug response can be influenced by genetic polymorphisms in metabolizing enzymes.
Purpose of the Study:
- To investigate the influence of CYP3A4 and CYP2C8 genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Malaysian subjects.
- To determine the association between specific CYP3A4 and CYP2C8 alleles and repaglinide's metabolic profile.
Main Methods:
- A total of 121 healthy Malaysian subjects received a single oral dose of 4 mg repaglinide.
- Serum repaglinide concentrations were measured at multiple time points using high-performance liquid chromatography.
- Subjects were genotyped for CYP3A4 (*4, *5, *18) and CYP2C8 (*2, *3, *4, *5) alleles using PCR-based methods.
Main Results:
- Allele frequencies for CYP2C8 and CYP3A4 variants were determined.
- No significant association was found between CYP2C8 or CYP3A4 genotypes and repaglinide's glucose-lowering effect.
- The CYP3A4*1/*18 genotype was associated with a significantly lower elimination rate constant and a higher half-life of repaglinide compared to the CYP3A4*1/*1 genotype.
Conclusions:
- Genetic polymorphisms in CYP3A4, specifically the CYP3A4*18 allele, significantly contribute to interindividual variability in repaglinide pharmacokinetics.
- CYP3A4 plays a substantial role in the metabolism of repaglinide.
- These findings have implications for personalized medicine approaches in diabetes management.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
106
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
106
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:27Pharmacogenetics of Drug Metabolism: Overview
138
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
138
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
208
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
208
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
147
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
147
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69